{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:12Z","timestamp":1791313272556,"version":"4.3.1"},"reference-count":53,"publisher":"Rockefeller University Press","issue":"6","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1998,9,21]]},"abstract":"<jats:p>Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng\/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth factor. IL-4 as well as IL-13 inhibited the migration of cultured bovine or human microvascular cells, showing unusual dose\u2013response curves that were sharply stimulatory at a concentration of 0.01 ng\/ml but inhibitory over a wide range of higher concentrations. Recombinant cytokine from mouse and from human worked equally well in vitro on bovine and human endothelial cells and in vivo in the rat, showing no species specificity. IL-4 was secreted at inhibitory levels by activated murine T helper (TH0) cells and by a line of carcinoma cells whose tumorigenicity is known to be inhibited by IL-4. Its ability to cause media conditioned by these cells to be antiangiogenic suggested that the antiangiogenic activity of IL-4 may play a role in normal physiology and contribute significantly to its demonstrated antitumor activity.<\/jats:p>","DOI":"10.1084\/jem.188.6.1039","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T16:49:30Z","timestamp":1027702170000},"page":"1039-1046","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":204,"title":["Inhibition of Angiogenesis by Interleukin 4"],"prefix":"10.1084","volume":"188","author":[{"given":"Olga V.","family":"Volpert","sequence":"first","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Fong","sequence":"additional","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa E.","family":"Koch","sequence":"additional","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Waltenbaugh","sequence":"additional","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Tepper","sequence":"additional","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl P.","family":"Bouck","sequence":"additional","affiliation":[{"name":"From the *Department of Microbiology-Immunology and \u2021Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and \u00a7Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[1998,9,21]]},"reference":[{"key":"2023072508151866800_B1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.V77.9.1859.1859","article-title":"Interleukin-4: a prototypic immunoregulatory lymphokine","volume":"77","author":"Paul","year":"1991","journal-title":"Blood"},{"key":"2023072508151866800_B2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/362245a0","article-title":"Disruption of the murine IL-4 gene blocks Th2 cytokine responses","volume":"362","author":"Kopf","year":"1993","journal-title":"Nature"},{"key":"2023072508151866800_B3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.1948049","article-title":"Generation and analysis of interleukin-4 deficient mice","volume":"254","author":"Kuhn","year":"1991","journal-title":"Science"},{"key":"2023072508151866800_B4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/325537a0","article-title":"Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage","volume":"325","author":"Ohara","year":"1987","journal-title":"Nature"},{"key":"2023072508151866800_B5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4049\/jimmunol.138.6.1813","article-title":"Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL-4): comparison of normal and recombinant, mouse and human IL-2 and BSF-1 (IL-4)","volume":"138","author":"Mosmann","year":"1987","journal-title":"J Immunology"},{"key":"2023072508151866800_B6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.immunol.14.1.179","article-title":"The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID","volume":"14","author":"Sugamura","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"2023072508151866800_B7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/07357909309018879","article-title":"Interleukin-4 and cancer therapy","volume":"11","author":"Puri","year":"1993","journal-title":"Cancer Investig"},{"key":"2023072508151866800_B8","first-page":"275","article-title":"Inhibition of colon and breast carcinoma cell growth by interleukin-4","volume":"52","author":"Toi","year":"1992","journal-title":"Cancer Res"},{"key":"2023072508151866800_B9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1172\/JCI116205","article-title":"Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in-vitro by interleukin-4","volume":"91","author":"Obiri","year":"1993","journal-title":"J Clin Invest"},{"key":"2023072508151866800_B10","first-page":"2173","article-title":"Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies","volume":"55","author":"Topp","year":"1995","journal-title":"Cancer Res"},{"key":"2023072508151866800_B11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/science.1636093","article-title":"An eosinophil-dependent mechanism for the antitumor effect of interleukin-4","volume":"257","author":"Tepper","year":"1992","journal-title":"Science"},{"key":"2023072508151866800_B12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0091-6749(94)90336-0","article-title":"The eosinophil-mediated antitumor activity of interleukin-4","volume":"94","author":"Tepper","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"2023072508151866800_B13","first-page":"3692","article-title":"Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice","volume":"55","author":"Schwarz","year":"1995","journal-title":"Cancer Res"},{"key":"2023072508151866800_B14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0008-8749(95)80036-I","article-title":"Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model","volume":"160","author":"Hillman","year":"1995","journal-title":"Cell Immunol"},{"key":"2023072508151866800_B15"},{"key":"2023072508151866800_B16","first-page":"3266","article-title":"Two competing influences that may explain concomitant tumor resistance","volume":"53","author":"Prehn","year":"1993","journal-title":"Cancer Res"},{"key":"2023072508151866800_B17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF01245372","article-title":"In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant","volume":"120","author":"Ohira","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023072508151866800_B18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O'Reilly","year":"1994","journal-title":"Cell"},{"key":"2023072508151866800_B19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"2023072508151866800_B20","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1073\/pnas.95.11.6343","article-title":"A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1","volume":"95","author":"Volpert","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023072508151866800_B21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<664::AID-IJC19>3.0.CO;2-B","article-title":"The paracrine role of tumor-derived mIL-4 on tumor-associated endothelium","volume":"72","author":"Saleh","year":"1997","journal-title":"Int J Cancer"},{"key":"2023072508151866800_B22","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood.V87.10.4286.bloodjournal87104286","article-title":"Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common \u03b3 chain","volume":"87","author":"Schnyder","year":"1996","journal-title":"Blood"},{"key":"2023072508151866800_B23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI118829","article-title":"IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the \u03b3c chain","volume":"98","author":"Palmer-Crocker","year":"1996","journal-title":"J Clin Invest"},{"key":"2023072508151866800_B24","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/intimm\/8.12.1915","article-title":"Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor","volume":"8","author":"Kotowicz","year":"1996","journal-title":"Int Immunol"},{"key":"2023072508151866800_B25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4049\/jimmunol.149.2.698","article-title":"Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells","volume":"149","author":"Swerlick","year":"1992","journal-title":"J Immunol"},{"key":"2023072508151866800_B26","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.4049\/jimmunol.156.7.2558","article-title":"Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human intestinal microvascular endothelial cells","volume":"156","author":"Haraldsen","year":"1996","journal-title":"J Immunol"},{"key":"2023072508151866800_B27","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.4049\/jimmunol.151.9.5062","article-title":"Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture","volume":"151","author":"Petzelbauer","year":"1993","journal-title":"J Immunol"},{"key":"2023072508151866800_B28","first-page":"166","article-title":"Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-\u03b1 or IL-4 and is not required for allograft rejection","volume":"147","author":"Bergese","year":"1995","journal-title":"Am J Pathol"},{"key":"2023072508151866800_B29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0006-291X(91)91561-P","article-title":"Interleukin-4 is a potent mitogen for capillary endothelium","volume":"174","author":"Toi","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"2023072508151866800_B30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/315333a0","article-title":"Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1","volume":"315","author":"Ohara","year":"1985","journal-title":"Nature"},{"key":"2023072508151866800_B31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0092-8674(86)90280-1","article-title":"Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development","volume":"45","author":"Leder","year":"1986","journal-title":"Cell"},{"key":"2023072508151866800_B32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(89)90925-2","article-title":"Murine interleukin-4 displays potent anti-tumor activity in vivo","volume":"57","author":"Tepper","year":"1989","journal-title":"Cell"},{"key":"2023072508151866800_B33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1","volume":"265","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"2023072508151866800_B34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0076-6879(91)98044-7","article-title":"Assay and purification of a naturally occurring inhibitor of angiogenesis","volume":"198","author":"Polverini","year":"1991","journal-title":"Methods Enzymol"},{"key":"2023072508151866800_B35","first-page":"1625","article-title":"A model of angiogenesis in the mouse cornea","volume":"37","author":"Kenyon","year":"1996","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2023072508151866800_B36","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1073\/pnas.83.24.9675","article-title":"Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1","volume":"83","author":"Finkelman","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023072508151866800_B37","doi-asserted-by":"crossref","first-page":"29265","DOI":"10.1074\/jbc.271.46.29265","article-title":"cDNA cloning and characterization of the human interleukin 13 receptor \u03b1 chain","volume":"271","author":"Aman","year":"1996","journal-title":"J Biol Chem"},{"key":"2023072508151866800_B38","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1074\/jbc.272.9.5487","article-title":"Tumor necrosis factor \u03b1 enhances the expression of the interleukin (IL)-4 receptor \u03b1-chain on endothelial cells increasing IL-4 or IL-13-induced Stat6 activation","volume":"272","author":"Lugli","year":"1997","journal-title":"J Biol Chem"},{"key":"2023072508151866800_B39","doi-asserted-by":"crossref","first-page":"22940","DOI":"10.1074\/jbc.272.36.22940","article-title":"An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4","volume":"272","author":"Orchansky","year":"1997","journal-title":"J Biol Chem"},{"key":"2023072508151866800_B40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1083\/jcb.122.2.497","article-title":"Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity","volume":"122","author":"Tolsma","year":"1993","journal-title":"J Cell Biol"},{"key":"2023072508151866800_B41","first-page":"4887","article-title":"Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin","volume":"56","author":"Gately","year":"1996","journal-title":"Cancer Res"},{"key":"2023072508151866800_B42","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1006\/bbrc.1997.7032","article-title":"Suppression of tumor growth with recombinant murine angiostatin","volume":"236","author":"Wu","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"2023072508151866800_B43","first-page":"1329","article-title":"A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer","volume":"57","author":"Sim","year":"1997","journal-title":"Cancer Res"},{"key":"2023072508151866800_B44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/37126","article-title":"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance","volume":"390","author":"Boehm","year":"1997","journal-title":"Nature"},{"key":"2023072508151866800_B45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1948050","article-title":"Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4","volume":"254","author":"Golumbek","year":"1991","journal-title":"Science"},{"key":"2023072508151866800_B46","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.151.8.4344","article-title":"Suppression of monocyte function and differential regulation of IL-1 and IL-1r\u03b1 by IL-4 contribute to resolution of experimental arthritis","volume":"151","author":"Allen","year":"1993","journal-title":"J Immunol"},{"key":"2023072508151866800_B47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/art.1780390516","article-title":"Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4","volume":"39","author":"van-Roon","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2023072508151866800_B48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng0895-430","article-title":"Gene therapy of metastatic cancer by in vivo retroviral gene targeting","volume":"10","author":"Hurford","year":"1995","journal-title":"Nature Genet"},{"key":"2023072508151866800_B49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-230X(08)60862-3","article-title":"How tumors become angiogenic","volume":"69","author":"Bouck","year":"1996","journal-title":"Adv Cancer Res"},{"key":"2023072508151866800_B50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1083\/jcb.138.3.707","article-title":"CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells","volume":"138","author":"Dawson","year":"1997","journal-title":"J Cell Biol"},{"key":"2023072508151866800_B51"},{"key":"2023072508151866800_B52"},{"key":"2023072508151866800_B53","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1073\/pnas.87.17.6624","article-title":"A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin","volume":"87","author":"Good","year":"1990","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/188\/6\/1039\/1690342\/98-0424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/188\/6\/1039\/1690342\/98-0424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T09:24:08Z","timestamp":1690277048000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/188\/6\/1039\/31385\/Inhibition-of-Angiogenesis-by-Interleukin-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9,21]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,9,21]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.188.6.1039","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9,21]]}}}